Prostate Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY25563
A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
To assess safety and tolerability in subjects with mCRPC to determine the MTD-R or MAD and to assess potential Phase 2 dose regimens and determine a RP2D-R. To assess the safety and tolerability of JANX007 when administered with recombinant human albumin (rHA). To compare the safety and tolerability of 2 potential RP2D-Rs identified from Part 1 and Part 2. To assess the safety and tolerability in taxane naïve subjects with mCRPC.
Study InformationSTUDY25698
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
To compare the efficacy of BMS-986365 vs investigator s choice of therapy. To compare the efficacy of BMS-986365 vs investigator s choice of therapy. Part 1 only: to inform the dose of BMS-986365 to continue in part 2 of the study. To further assess the efficacy of BMS-986365 vs investigator s choice of therapy. To investigate the effect on PROs in this study population when treated with BMS-986365 vs investigator's choice of therapy.
Study InformationSTUDY26050
A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer
To determine whether treatment with AAA817+ARPI prolongs radiographic progression free survival (rPFS) as assessed by Prostate Cancer Working Group 3 (PCWG3)- modified RECIST v1.1, in participants with PSMA-positive mCRPC, treated with another ARPI as last treatment as compared to participants treated with investigator?s choice of standard of care.
Study InformationSTUDY26175
A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH)
To compare overall survival in participants with mCSPC who are receiving standard of care ADT (between 6-12 months exposure) + ARPI and have suboptimal PSA response with those who recieve standard of care ADT + ARPI plus docetaxel chemotherapy.
Study InformationSTUDY26318
NRG-GU013: The Phase III High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
To compare metastasis-free survival, determined using conventional imaging, between men with high-risk prostate cancer randomized to ultrahypofractionation (SBRT) to those randomized to moderate hypofractionation and conventional fractionation
Study InformationSTUDY26341
WATER IV Prostate Cancer: Aquablation versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer
To evaluate the safety and efficacy of Aquablation Therapy with the AQUABEAM Robotic System and the HYDROS Robotic System to reduce treatment related harm in men with Grade Group (GG) 1 to 3 localized prostate cancer who are candidates for, or have selected, prostatectomy.
Study InformationSTUDY26541
Hypofractionated Radiotherapy with a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
To evaluate the incidence of CTCAE grade 2 or higher acute genitourinary (GU) toxicity.
Study Information